Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i EVENTS
26 august 2017, Barcelona, Spain
ESC 2017: New approaches to targeting residual cardiovascular risk
Read full report..
R3i editorial
27 April 2018

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Residual cardiovascular risk: refocus on a multifactorial approachRead more...

Guidelines focus on reducing low-density lipoprotein cholesterol (LDL-C), given indisputable evidence that this is a key driver of both clinical and subclinical atherosclerotic cardiovascular disease (ASCVD).
Yet it is also recognized that even with optimal LDL-C lowering therapy, a high residual cardiovascular risk persists. Estimates of the magnitude of this residual cardiovascular risk are mainly derived by clinical trial databases.
However, given that clinical trials tend to enrol a homogeneous patient population, it is unclear whether findings from trials regarding the residual cardiovascular risk on lipid-lowering therapy (LLT) are relevant to the general population.
landmark study
27 April 2018

EVAPORATE: Effect of Vascepa on Improving Coronary Atherosclerosis in People with High Triglycerides Taking Statin Therapy Read more...

While statin therapy is undoubtedly efficacious in lowering LDL-C levels, reducing the progression and promoting regression of atherosclerosis, and reducing cardiovascular risk, it is also recognized that a substantial residual cardiovascular risk persists.3 This underlines the need for additional intervention, targeting other risk factors beyond...
focus on...
27 April 2018

Quantifying residual risk on long-term lipid-lowering therapy Read more...

There is indisputable evidence that LDL-C is causal for atherosclerotic CVD, and therefore guidelines for CVD prevention focus on LDL-C lowering therapeutic strategies as one of the key approaches for reducing cardiovascular risk.1-3 Statins, the first-line LDL-C lowering therapy, are efficacious in reducing cardiovascular risk.4...
SCIENTIFIC SESSIONS
Looking to the American College of Cardiology Scientific Sessions 2018
67th Annual Scientific Sessions of the American College of Cardiology, 10-12 March, Orlando, USA.
Read more..
This year’s Scientific Sessions offers new insights from CANTOS and COMPASS, as well as novel approaches targeting elevated triglycerides and lipoprotein(a). Added to this, the second of the cardiovascular outcomes studies with PCSK9 monoclonal antibody therapy, ODYSSEY Outcomes with alirocumab in patients with a recent acute coronary syndrome, is keenly anticipated.
recent publication

ODYSSEY Outcomes: a key feature of the 67th Annual Scientific Sessions of the American College of Cardiology, 10-12 March, Orlando, USA Read more...

Presentation of top-line results from ODYSSEY Outcomes, showed that treatment with the PCSK9 inhibitor alirocumab improved major adverse cardiovascular events...
recent publication

TNT analysis: Higher triglyceride-rich lipoprotein-cholesterol associated with increased cardiovascular riskRead more...

This post hoc analysis of the Treating to New Targets (TNT) study showed that reduction in triglyceride-rich lipoprotein-cholesterol (TRL-C) with...
recent publication

More news from ANCHOR: Focus on women with high triglyceridesRead more...

This sub analysis from the ANCHOR study showed that treatment with 4 g/day icosapent ethyl, a pure prescription eicosapentaenoic acid...
recent publication

Targeting triglycerides: therapeutic potential of ANGPTL3 and apoC-III?Read more...

This timely review has highlighted the potential of therapeutic approaches targeting angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) to...
recent publication

Atherogenic dyslipidaemia prevalent in ChinaRead more...

Increasing obesity rates in China has led to increases in the prevalence of elevated triglycerides and low high-density lipoprotein cholesterol...
recent publication

Obesity a driver of inadequate control of triglycerides in younger diabetes subjects in JapanRead more...

New findings from the Shiga Diabetes Clinical Survey implicate obesity as a driver of poorer glycaemic and triglycerides control among...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.